Inactief instrument

Andere talen KetamineOne Capital Deutsche Boerse AG

Aandelen

MY00

CA4925531028

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference	19-06-23
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group	16-06-23
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	16-06-23
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference	25-05-23
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response	03-05-23
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	18-04-23
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18-04-23
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval	11-04-23
Wellbeing Announces Cease Trade Order	06-04-23
IIROC Trading Halt - MEDI	06-04-23
Wellbeing Provides Bi-Weekly Default Status Report	16-03-23
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference	16-03-23
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion	13-03-23
Wellbeing Digital to Participate in The Global Biomedical Design Conference	09-03-23
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout	08-03-23
Wellbeing Provides Bi-Weekly Default Status Report	02-03-23
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event	01-03-23
Wellbeing Provides Bi-Weekly Default Status Report	16-02-23
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.	15-02-23
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial	14-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen KetamineOne Capital Deutsche Boerse AG

Aandelen

MY00

CA4925531028

Andere talen

Filters